Latest news and press releases about Cingulate Inc. (CING): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine).
Price
| Price | $5.09 |
| Market Cap | $69M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.13 |
| EV / EBITDA | -1.10 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -894.81% |
| Return on Invested Capital | -176.51% |
| Return on Assets | -148.94% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALLR · BCTX · CASI · CLSD · ENTO · KAPA · LEXX
Explore sector: Healthcare · Biotechnology
More sections of CING: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks